Skip to main content
. Author manuscript; available in PMC: 2021 Dec 10.
Published in final edited form as: Gynecol Oncol. 2021 Jun 6;162(2):249–255. doi: 10.1016/j.ygyno.2021.05.038

Table 2.

Results of the Markov cohort model for patients with microsatellite stable endometrial cancer.

N = 5000 each cohort Pembrolizumab/Lenvatinib Carboplatin/Paclitaxel
Respond (n) 1106 1626
Progress (n) 742 622
Death (n) 3151 2752
Cost ($) 261,518 48,848
Difference in costs 212,670
Effectiveness (QALY) 1.40 1.68
Difference in QALYs −0.28